Browse News
Filter News
Found 2,651 articles
-
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
2/3/2023
Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
-
Wednesday, the FDA approved GSK’s daprodustat, now to be marketed as Jesduvroq, for the treatment of anemia due to chronic kidney disease in adult patients.
-
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
2/2/2023
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), today announced that Mr. James Foster , Chief Executive Officer of Virax, has issued a letter to shareholders.
-
GSK has dropped two assets, an investigational celiac disease therapeutic and a Staphylococcus aureus vaccine hopeful, from its pipeline.
-
Pfizer reported full-year 2022 earnings Tuesday and provided 2023 projections far below the previous year's totals.
-
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
1/31/2023
Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).
-
Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
1/31/2023
Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus infection.
-
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
1/31/2023
Enanta Pharmaceuticals, Inc . today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023.
-
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
1/31/2023
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP test to aid in the diagnosis of CHF across Europe.
-
The FDA granted Moderna's RSV vaccine candidate Breakthrough Therapy Designation Monday.
-
Masimo Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)
1/30/2023
Masimo (NASDAQ: MASI) today announced the limited market release of Visual Clinical Activity Monitoring (VCAM™), a video analysis system that uses artificial intelligence to help facilitate compliance with hospital hand hygiene protocols.
-
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
1/30/2023
Moderna, Inc. today announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.
-
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA
1/26/2023
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of ASC10 for monkeypox indication.
-
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
1/25/2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).
-
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
1/17/2023
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults.
-
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
1/17/2023
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients.
-
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
1/16/2023
Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on the commercialization of SCB-2019 in China and strategic priorities in 2023.
-
InvisiShield Technologies Announces Scientific Advisory Board
1/11/2023
InvisiShield Technologies Ltd. today announced its Scientific Advisory Board (SAB) which is comprised of four experts in immunology and virology, including two Nobel Laureates.
-
LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer
1/11/2023
LEX Diagnostics announces the appointment of Ed Farrell as its new Chief Executive Officer.
-
JPM Day 2: Highlights
1/10/2023
Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week.